STAT+: The biotech scorecard for the first quarter: 19 stock-moving events to watch

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial. This quarter, the company hopes to follow up those positive results with the readout of a second, Phase 3 study.

Continue to STAT+ to read the full story…